Drug intelligence / Profile preview

VLP-SA-Aβ1-40

Development stage: Preclinical
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

**VLP-SA-Aβ1-40** is a candidate vaccine composed of **virus-like particles (VLPs)** displaying the amyloid-beta 1-40 (Aβ1-40) peptide, designed to induce an immune response against Aβ1-40 for the treatment or prevention of **Alzheimer's disease**. The VLP core is typically coupled to the Aβ1-40 peptide via a linkage system (commonly SpyCatcher/SpyTag or SA/Streptavidin for “SA”), forming a repetitive display that elicits B-cell and T-cell immune responses. The vaccine mechanism aims to generate **anti-Aβ1-40 antibodies**, which can bind and help clear amyloid-beta plaques from the brain, a pathological hallmark of Alzheimer's disease[9][13]. VLP-based vaccines show promise for strong immunogenicity and safety profiles due to their particulate nature and ability to display antigenic peptides in a highly immunogenic format[5][7][9][13]. The primary indication for this drug is **Alzheimer's disease**, with ongoing preclinical and early clinical development.

Other names: virus-like particle-SA-amyloid-beta 1-40VLP-SA-Aβ1-40

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on VLP-SA-Aβ1-40.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VLP-SA-Aβ1-40.

Explore the full profile